Home > For Consumers > Minocycline for acne vulgaris: efficacy...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-.

Cochrane Database of Systematic Reviews: Plain Language Summaries.

Minocycline for acne vulgaris: efficacy and safety

This version published: 2013; Review content assessed as up-to-date: November 08, 2011.

Plain language summary

Acne is the most common skin disease of adolescence, and in most cases it clears spontaneously. However, in some people it persists in to adulthood. There are many different treatment options, but there is little good evidence to inform doctors and individuals about which to choose.

Minocycline was the most prescribed antibiotic used to treat acne because it was thought to be better than other options, despite the original version of this review finding no reliable evidence that it was any better than other treatments. Over recent years it has been used less, which was due to serious concerns about its safety, including skin pigmentation, which in some cases is irreversible. It was also more expensive than other treatments.

Since the first version of this review, minocycline's cost has fallen. In the UK, the daily cost of generic minocycline is now one third the cost of tetracycline. This update was undertaken to identify whether there was any new evidence that might change the conclusions of the original review or provide information on risks associated with minocycline therapy. Twelve new RCTs were identified, making a total of 39 RCTs (6013 participants).

In summary, there is no evidence to support the first‐line use of minocycline in the treatment of acne. All of the trials showed that, on average, people treated with minocycline experienced an improvement in their acne. However, no study conclusively showed any important clinical difference between minocycline or other commonly‐used therapies. The analysis found that minocycline may act more quickly than oxytetracycline or tetracycline, but there is no overall difference in the end. There is no evidence that it is more effective in acne that is resistant to other therapies, or that the effects last longer. Although it is often claimed that the more expensive once‐daily slow‐release preparation is a more attractive option to teenagers with acne, the evidence in this review does not show it to be any better or safer compared to other oral antibiotics that have to be taken more frequently.

Despite a thorough search for evidence, it is still not known which of the tetracyclines are the safest to take overall as they are all associated with side‐effects. The only conclusion that we could make was that people treated with minocycline for acne are at a significantly greater risk of developing an autoimmune (lupus‐like) syndrome than those given tetracycline or no treatment.

Abstract

Background: Minocycline is an oral antibiotic used for acne vulgaris. Its use has lessened due to safety concerns (including potentially irreversible pigmentation), a relatively high cost, and no evidence of any greater benefit than other acne treatments. A modified‐release version of minocycline is being promoted as having fewer side‐effects.

Objectives: To assess new evidence on the effects of minocycline for acne vulgaris.

Search methods: Searches were updated in the following databases to November 2011: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library, MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We also searched trials registers and checked reference lists for further references to relevant randomised controlled trials (RCTs).

The Cochrane Skin Group's Trials Search Co‐ordinator undertook searches exploring minocycline's adverse effects in EMBASE and MEDLINE in February 2012.

Selection criteria: We selected randomised controlled trials (RCTs) comparing minocycline, at any dose, to an active or a placebo control, in participants with inflammatory acne vulgaris. For adverse effects, we selected additional studies that reported the number of adverse effects and the number of participants treated.

Data collection and analysis: Outcome measures used in the trials included lesion counts, acne grades/severity scores, doctors' and participants' global assessments, adverse effects, and dropout rates. Two authors independently assessed the quality of each study. Effect sizes were calculated, and meta‐analyses were undertaken where possible.

Sixteen studies met the inclusion criteria for the review of adverse effects.

Main results: We included 12 new RCTs for this update, giving a total of 39 RCTs (6013 participants). These additional 12 RCTs have not changed the original conclusions about the clinical efficacy of minocycline.

The identified RCTs were generally small and poor quality. Meta‐analysis was rarely possible because of the lack of data and different outcome measures and trial durations. Although minocycline was shown to be an effective treatment for moderate to moderately‐severe acne vulgaris, there was no evidence that it is better than any of the other commonly‐used acne treatments. One company‐sponsored RCT found minocycline to be less effective than combination treatment with topical erythromycin and zinc. No trials have been conducted using minocycline in those participants whose acne is resistant to other therapies. Also, there is no evidence to guide what dose should be used.

The adverse effects studies must be interpreted with caution. The evidence suggests that minocycline is associated with more severe adverse effects than doxycycline. Minocycline, but not other tetracyclines, is associated with lupus erythematosus, but the risk is small: 8.8 cases per 100,000 person‐years. The risk of autoimmune reactions increases with duration of use. The evidence does not support the conclusion that the more expensive extended‐release preparation is safer than standard minocycline preparations.

Authors' conclusions: Minocycline is an effective treatment for moderate to moderately‐severe inflammatory acne vulgaris, but there is still no evidence that it is superior to other commonly‐used therapies. This review found no reliable evidence to justify the reinstatement of its first‐line use, even though the price‐differential is less than it was 10 years ago. Concerns remain about its safety compared to other tetracyclines.

Editorial Group: Cochrane Skin Group.

Publication status: Edited (no change to conclusions).

Citation: Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD002086. DOI: 10.1002/14651858.CD002086.pub2. Link to Cochrane Library. [PubMed: 22895927]

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...